Xponance Inc. Has $492,000 Stock Holdings in Perrigo Company plc (NYSE:PRGO)

Xponance Inc. lowered its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 6.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,141 shares of the company’s stock after selling 1,368 shares during the period. Xponance Inc.’s holdings in Perrigo were worth $492,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. M&R Capital Management Inc. grew its position in shares of Perrigo by 3.0% during the 1st quarter. M&R Capital Management Inc. now owns 14,717 shares of the company’s stock worth $474,000 after buying an additional 434 shares during the period. Retirement Systems of Alabama grew its holdings in Perrigo by 0.3% in the first quarter. Retirement Systems of Alabama now owns 170,162 shares of the company’s stock worth $5,478,000 after purchasing an additional 447 shares during the period. Ridgewood Investments LLC increased its stake in Perrigo by 1.3% in the first quarter. Ridgewood Investments LLC now owns 35,140 shares of the company’s stock valued at $1,131,000 after purchasing an additional 451 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Perrigo by 4.3% during the first quarter. Park Avenue Securities LLC now owns 11,330 shares of the company’s stock valued at $365,000 after purchasing an additional 465 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Perrigo by 1.9% during the second quarter. Arizona State Retirement System now owns 37,939 shares of the company’s stock valued at $974,000 after purchasing an additional 699 shares during the period. 95.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Perrigo

In other news, EVP Svend Andersen sold 28,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $27.75, for a total value of $785,325.00. Following the completion of the transaction, the executive vice president now directly owns 73,553 shares of the company’s stock, valued at $2,041,095.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Perrigo news, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the sale, the director now owns 6,009 shares of the company’s stock, valued at $164,045.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Svend Andersen sold 28,300 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $27.75, for a total transaction of $785,325.00. Following the completion of the transaction, the executive vice president now owns 73,553 shares in the company, valued at $2,041,095.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,254 shares of company stock worth $1,411,969. Insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

PRGO has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.00 target price (down from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Piper Sandler lowered their target price on Perrigo from $36.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $42.00 price target on shares of Perrigo in a research report on Monday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Perrigo presently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Perrigo Stock Performance

Shares of PRGO opened at $26.23 on Tuesday. Perrigo Company plc has a 52 week low of $24.82 and a 52 week high of $34.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.24 and a current ratio of 1.99. The stock has a 50 day moving average price of $27.75 and a two-hundred day moving average price of $28.62. The firm has a market capitalization of $3.58 billion, a P/E ratio of -374.71 and a beta of 0.49.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Friday, August 2nd. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. Perrigo’s revenue was down 10.7% compared to the same quarter last year. Equities analysts forecast that Perrigo Company plc will post 2.57 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th were given a $0.276 dividend. This represents a $1.10 dividend on an annualized basis and a yield of 4.21%. The ex-dividend date was Friday, August 30th. Perrigo’s payout ratio is -1,571.43%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.